Curis, Inc.

507 articles about Curis, Inc.

• Curis to Host Virtual Event to Discuss Updated Clinical Data for CA-4948 in AML/MDS Presented at EHA

  6/4/2021

  - KOL Event featuring Dr. Guillermo Garcia-Manero scheduled for Friday, June 11 at 8:00 am ET - - Discussion of data from Phase 1/2 study of CA-4948 in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) -

• Curis, Inc. Announces 2021 Virtual Symposium: "VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond"

  6/1/2021

  Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced the virtual symposium, "VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond," taking place on June 18, 2021, 9:00-1:15 PM ET.

• Curis to Present at Jefferies Virtual Healthcare Conference - May 25, 2021

  5/25/2021

  Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced that announced that James Dentzer, President and Chief Executive Officer of Curis, will participate in a virtual fireside chat at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 3:00 p.m. ET.

• Curis Reports First Quarter 2021 Financial Results

  5/12/2021

  Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the first quarter ended March 31, 2021.

• Curis to Release First Quarter 2021 Financial Results and Hold Conference Call on May 12, 2021

  5/5/2021

   Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its first quarter 2021 financial results on Wednesday, May 12, 2021 , after the close of US markets.

• Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS

  4/19/2021

  Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for CA-4948, a first-in-class, small molecule inhibitor of IR

• Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Apr 07, 2021

  4/7/2021

  Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced that on April 1, 2021, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 167,300 shares of Curis common stock to five new employees, with a grant date of April 1, 2021.

• Curis to Present at 20th Annual Needham Virtual Healthcare Conference

  4/6/2021

   Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer , President and Chief Executive Officer of Curis, will present a company overview at the 20th Annual Needham Virtual Healthcare Conference on Tuesday, April 13,

• Curis Reports Fourth Quarter and Year-End 2020 Financial Results

  3/16/2021

  Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, reported its financial results for the fourth quarter and year ended December 31, 2020.

• Curis Announces Abstract for CA-4948 Accepted for Presentation at the American Association for Cancer Research Annual Meeting

  3/10/2021

  Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that an abstract for CA-4948, a small molecule IRAK4 inhibitor, has been accepted for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting

• Curis to Release Fourth Quarter 2020 Financial Results and Hold Conference Call on March 16, 2021

  3/9/2021

  Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its fourth quarter 2020 financial results on Tuesday, March 16, 2021 , after the close of US markets.

• Curis to Present at H.C. Wainwright & Co. Global Life Sciences Conference

  3/2/2021

  Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer , President and Chief Executive Officer of Curis, will present a company overview at the H.C. Wainwright & Co. Global Life Sciences Conference.

• Curis to Present at SVB Leerink 10th Annual Global Healthcare Conference

  2/19/2021

  Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present a company overview at the SVB Leerink 10th Annual Global Healthcare Conference

• Curis Doses First Patient in Phase 1 Study of CA-4948 in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies

  2/9/2021

  Curis, Inc. announced that the first patient has been dosed in its Phase 1 trial evaluating CA-4948, a novel, small molecule IRAK4 kinase inhibitor, in combination with ibrutinib, a BTK inhibitor, in patients with relapsed or refractory hematologic malignancies.

• Curis Announces Initiation of Investigator-Sponsored Phase 2 LUCAS Study of CA-4948 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate-Risk Myelodysplastic Syndromes

  2/2/2021

  Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the initiation of a Phase 2 investigator-sponsored trial (IST) evaluating CA-4948,

• Curis to Present at B. Riley Securities Virtual Oncology Investor Conference

  1/14/2021

  Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer , President and Chief Executive Officer of Curis, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference on Thursd

• Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Jan 08, 2021

  1/8/2021

  Curis, Inc. announced that on January 4, 2021, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 185,000 shares of Curis common stock to three new employees, with a grant date of January 4, 2021.

• Curis Announces Closing of Public Offering of Common Stock with $169.6 Million in Gross Proceeds, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

  12/14/2020

  Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the closing of its underwritten public offering of 29,500,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase up to an additional 3,847,826 shares,

• Curis Announces Pricing of Public Offering of Common Stock - Dec 09, 2020

  12/9/2020

  Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced the pricing of an underwritten public offering of 25,652,174 shares of its common stock at a public offering price of $5.75 per share for total gross proceeds of approximately $147.5 million.

• Curis Announces Proposed Public Offering of Common Stock - Dec 08, 2020

  12/8/2020

  Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced its intention to offer and sell shares of its common stock in an underwritten public offering pursuant to an existing shelf registration statement.